Biogen Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BIIB Nasdaq 2836 www.biogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biogen Inc.

Why Is Biogen (BIIB) Up 3.8% Since Last Earnings Report? - May 29th, 2026 9:30 am
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts - May 25th, 2026 6:06 pm
MarketBeat Week in Review – 05/18 - 05/22 - May 23rd, 2026 5:00 am
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks - May 22nd, 2026 2:15 pm
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails - May 22nd, 2026 10:14 am
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish - May 22nd, 2026 5:50 am
Parkinson’s drug from Biogen, Denali comes up short - May 22nd, 2026 4:46 am
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - May 21st, 2026 5:03 pm
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease - May 21st, 2026 4:00 pm
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - May 19th, 2026 7:33 am
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors - May 19th, 2026 4:30 am
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus - May 18th, 2026 10:34 pm
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - May 18th, 2026 1:17 pm
Goldman Sachs sets new Biogen stock price target on bold Alzheimer's bet - May 17th, 2026 2:33 pm
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal - May 15th, 2026 9:28 am
Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls - May 15th, 2026 7:45 am
Biogen completes $5.3B Apellis Pharmaceuticals acquisition - May 15th, 2026 5:44 am
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer's Pathologies in Biogen's Phase 2 Tau Study - May 14th, 2026 6:48 pm
Biogen Shares Jump 10% After Advancing Alzheimer's Tau Drug - May 14th, 2026 5:19 pm
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push - May 14th, 2026 5:10 pm